BFRI Biofrontera Future Profit

BFRI (Biofrontera Inc) - company brandmark

Biofrontera Inc. is expanding its reach through strategic alliances with leading US dermatological centers, confirming the projected volume of future profits. High physician confidence in the Ameluz system strengthens the brand's position, while strict medical protocols guarantee stable sales of high-margin components. The value of 0.01 indicates the company's current level of expected revenues.

Biofrontera Inc (BFRI): Company Profit Forecast from 03/22/2025 to 11/12/2026

BFRI (Biofrontera): analytical breakdowns and indicator data

- share price and consensus valuation forecast:
Stock Price Biofrontera, Inc.|BFRI - Analyst Consensus Forecast
- market capitalization data:
Market Valuation Biofrontera|BFRI - Value Adjusted for Debt and Cash
- book capitalization information:
Net Assets per Single Share Biofrontera|BFRI - Book Valuation of Business|Market Value to Book Value Ratio biofrontera-us.com|BFRI - Company Total Assets
- company total debt and liquidity indicators:
Total Debt to Capital Biofrontera Inc.|BFRI - Ratio of Long-Term Indebtedness to Capital|Short-Term Debt to Equity Biofrontera, Inc.|BFRI - Company Aggregate Debt|Debts to Book Capitalization Biofrontera|BFRI - Company Long-Term Debt|Company Short-Term Debts Biofrontera|Quick Liquidity biofrontera-us.com
- net income and valuation ratios data:
BFRI - Company Net Income|Projected Future Earnings Biofrontera Inc.|BFRI - Market Cap to Net Income|Future Price to Earnings Biofrontera, Inc.|BFRI - Growth-Adjusted Payback Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Biofrontera|BFRI - Profit before interest, taxes and amortization|Earnings per share for the last twelve months Biofrontera|BFRI - Earnings per share for the last 12 months|Year-over-year net earnings per share growth for the last 12 months biofrontera-us.com|BFRI - Net earnings per one share growth for the current year|Earnings growth forecast for next year Biofrontera Inc.
General company analysis:Biofrontera Inc., BFRI
Finished products of Biofrontera, Inc.

Biofrontera Inc. is optimizing costs by outsourcing ointment logistics to third-party operators. This indicator measures the dynamics of expected net income, synthesizing market forecasts into a daily data stream. The analyst distinguishes fundamental stability from volatility, assessing the smoothness of the trend as a sign of business maturity. The stability of these metrics confirms the effectiveness of seamless partner integration. Extrapolating future profits allows for an objective assessment of growth potential without time lags.

Key competitors

KRYS (Krystal Biotech, Inc.) - Projected Future Earnings|Projected Future Earnings apogeetherapeutics.com|Future Profit ARQT (Arcutis Biotherapeutics, Inc.)|VCEL (Vericel Corp) - Expected Net Income|Expected Profit Oruka Corp ORKA|Company Profit Forecast Sanara MedTech, Inc. (SMTI)|DBVT - Expected Profit|SLSN - Projected Future Earnings|DERM: Projected Future Earnings|FBRX - Company Profit Forecast|Expected Profit Empro|Net Profit Forecast SLGL (Sol-Gel Technologies, Ltd.)|Projected Future Earnings AXIL|Expected Profit MDCX (medicuspharma.com)|Projected Future Earnings VRCA (Verrica Pharmaceuticals Inc.)|Company Profit Forecast Hoth Therapeutics Inc. (HOTH)|VYNE - Expected Profit|Expected Net Profit Sonoma Pharmaceuticals|QNRX: Projected Future Earnings|Forward Earnings AZTR (azitrainc.com)|Expected Profit Dermata Therapeutics, Inc.|ELAB: Expected Net Income|Expected Profit Revance Therapeutics, Inc (RVNC)